| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Poly:Kanamycin targets Toll-like receptor 3 (TLR3), a pattern recognition receptor that recognizes double-stranded RNA and triggers innate immune responses. Poly(I:C) acts as a TLR3 agonist, inducing the production of type I interferons and pro-inflammatory cytokines. It also activates RIG-I and MDA5, other cytosolic RNA sensors. Kanamycin in the mixture serves to stabilize the Poly(I:C) and does not contribute to the TLR3-targeting activity.
|
|---|---|
| ln Vitro |
In vitro, Poly:Kanamycin acts as a TLR3 agonist, stimulating immune responses in cells expressing TLR3. Poly(I:C) induces the production of type I interferons and pro-inflammatory cytokines in various cell types, including dendritic cells, macrophages, and epithelial cells. Kanamycin stabilizes the Poly(I:C) molecule, enhancing its activity. The compound has been used to study innate immune responses and as a vaccine adjuvant.
|
| ln Vivo |
In vivo, Poly:Kanamycin has been used as a vaccine adjuvant to enhance innate and adaptive immune responses. Poly(I:C) sodium can induce apoptosis in cancer cells. The compound has potential applications in cancer immunotherapy and vaccine development. However, specific in vivo efficacy data and dosing regimens are not extensively detailed.
|
| Enzyme Assay |
There are no specific in vitro enzyme or receptor binding assays for Poly:Kanamycin as a drug target. TLR3 activation is typically assessed using reporter cell lines expressing TLR3 and a NF-κB or IRF-driven luciferase reporter. Cells are treated with Poly:Kanamycin (typically 1-100 μg/mL) for 6-24 hours, and luciferase activity is measured. Cytokine production (IFN-β, IL-6, TNF-α) is measured by ELISA or Luminex.
|
| Cell Assay |
In vitro cellular assays for Poly:Kanamycin use cell lines expressing TLR3 (e.g., HEK293-TLR3, dendritic cells, macrophages). Cells are cultured in appropriate media and treated with various concentrations of Poly:Kanamycin (typically 1-100 μg/mL) for 6-24 hours. Cytokine production is measured by ELISA or qPCR. NF-κB and IRF activation is assessed by reporter assays or Western blotting. Cell viability is assessed using MTT assays.
|
| Animal Protocol |
In vivo animal studies with Poly:Kanamycin would typically use mouse models of infection, cancer, or vaccination. The compound is administered intranasally, intraperitoneally, or intramuscularly at doses of 10-100 μg per mouse. Immune responses (cytokine production, antibody titers, T cell responses) are assessed. In cancer models, tumor growth and survival are monitored. However, specific protocols are not extensively detailed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Poly:Kanamycin are not applicable as it is a mixture of a nucleic acid polymer and an antibiotic. Poly(I:C) is a large polymer that is rapidly cleared from circulation. Kanamycin, when administered, is poorly absorbed orally and is primarily excreted unchanged in urine. The mixture is used as a research tool rather than a drug.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Poly:Kanamycin is not extensively reported. Poly(I:C) can cause inflammatory responses and fever at high doses. Kanamycin is an aminoglycoside antibiotic with potential nephrotoxicity and ototoxicity. The compound is for research use only and not for human therapeutic use. Standard toxicity studies would include assessment of inflammatory responses and organ function.
|
| References | |
| Additional Infomation |
Poly:Kanamycin is a mixture of poly(I:C) and kanamycin in a 1:1 molar ratio. Poly(I:C) is a synthetic dsRNA that acts as a TLR3 agonist, inducing innate immune responses. Kanamycin stabilizes the Poly(I:C) molecule. The compound is used as a vaccine adjuvant and in cancer immunotherapy research. It is available for research purposes only.
|
| Molecular Formula |
NA
|
|---|---|
| Molecular Weight |
NA
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
